Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3056% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 43.8Yield 5.61%
Pfizer Total Biopharma Royalty Revenues by Year
Total Biopharma Royalty Revenues (cross-portfolio summary) — International reported YoY (%) (%)
Pfizer Total Biopharma Royalty Revenues: 94.0% in FY2025.
Latest, FY2025
94.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“|| Total Royalty revenues included above | $ | 1,650 | $ | 1,423 | 16% | 16% | $ | 1,639 | $ | 1,418 | 16% | $ | 11 | $ | 6 | 94% | 91%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Biopharma Royalty Revenues (cross-portfolio summary) — International reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 94.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Pfizer Total Biopharma Royalty Revenues (%), annual FY2025–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/royalty-rev-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?